BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 25734660)

  • 1. Promising management of pazopanib-induced liver toxicity.
    Vlenterie M; van Erp NP; van der Graaf WT
    Acta Oncol; 2015 Jul; 54(7):1064-6. PubMed ID: 25734660
    [No Abstract]   [Full Text] [Related]  

  • 2. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
    Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T
    Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report.
    Verschoor AJ; Warmerdam FARM; Bosse T; Bovée JVMG; Gelderblom H
    BMC Cancer; 2018 Jan; 18(1):92. PubMed ID: 29357824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to pazopanib in two pediatric patients with pretreated relapsing synovial sarcoma.
    Casanova M; Basso E; Magni C; Bergamaschi L; Chiaravalli S; Carta R; Tirtei E; Massimino M; Fagioli F; Ferrari A
    Tumori; 2017 Jan; 103(1):e1-e3. PubMed ID: 27647230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy.
    Gerullis H; Eimer C; Ecke TH; Georgas E; Arndt C; Otto T
    Anticancer Drugs; 2013 Apr; 24(4):422-5. PubMed ID: 23407060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of refractory Ewing sarcoma to pazopanib.
    Alcindor T
    Acta Oncol; 2015 Jul; 54(7):1063-4. PubMed ID: 25345493
    [No Abstract]   [Full Text] [Related]  

  • 7. A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities.
    Haas RL; Gelderblom H; Sleijfer S; van Boven HH; Scholten A; Dewit L; Borst G; van der Hage J; Kerst JM; Nout RA; Hartgrink HH; de Pree I; Verhoef C; Steeghs N; van Coevorden F
    Acta Oncol; 2015; 54(8):1195-201. PubMed ID: 25920360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose administration of oral pazopanib for the treatment of recurrent angiosarcoma.
    Miura H; Shirai H
    Clin Exp Dermatol; 2015 Jul; 40(5):575-7. PubMed ID: 25753734
    [No Abstract]   [Full Text] [Related]  

  • 9. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.
    Necchi A; Mariani L; Zaffaroni N; Schwartz LH; Giannatempo P; Crippa F; Morosi C; Lanocita R; Sava T; Ortega C; Messina C; Sacco C; Pennati M; Daidone MG; Nicolai N; De Braud F; Gianni AM; Salvioni R
    Lancet Oncol; 2012 Aug; 13(8):810-6. PubMed ID: 22819172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.
    Sternberg CN; Davis ID; Deen KC; Sigal E; Hawkins RE
    Oncology; 2014; 87(6):342-50. PubMed ID: 25227656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uterine sarcoma with posterior reversible encephalopathy syndrome associated with pazopanib.
    Tatsumichi T; Tanaka H; Okazaki T; Takahashi K; Suzuki K; Kawakita K; Houchi H; Kuroda Y; Kosaka S
    J Clin Pharm Ther; 2021 Feb; 46(1):223-226. PubMed ID: 33044009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
    Monk BJ; Mas Lopez L; Zarba JJ; Oaknin A; Tarpin C; Termrungruanglert W; Alber JA; Ding J; Stutts MW; Pandite LN
    J Clin Oncol; 2010 Aug; 28(22):3562-9. PubMed ID: 20606083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment.
    Nakano K; Inagaki L; Tomomatsu J; Motoi N; Gokita T; Ae K; Tanizawa T; Shimoji T; Matsumoto S; Takahashi S
    Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):357. PubMed ID: 24630810
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetic drug evaluation of pazopanib for the treatment of uterine leiomyosarcomas.
    Ferrero S; Leone Roberti Maggiore U; Aiello N; Barra F; Ditto A; Bogani G; Raspagliesi F; Lorusso D
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):881-889. PubMed ID: 28678537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients.
    Klempner SJ; Choueiri TK; Yee E; Doyle LA; Schuppan D; Atkins MB
    J Clin Oncol; 2012 Sep; 30(27):e264-8. PubMed ID: 22802316
    [No Abstract]   [Full Text] [Related]  

  • 16. Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibition-Induced Hypertension: The HYPAZ Trial.
    Mäki-Petäjä KM; McGeoch A; Yang LL; Hubsch A; McEniery CM; Meyer PAR; Mir F; Gajendragadkar P; Ramenatte N; Anandappa G; Santos Franco S; Bond SJ; Schönlieb CB; Boink Y; Brune C; Wilkinson IB; Jodrell DI; Cheriyan J
    Hypertension; 2021 May; 77(5):1591-1599. PubMed ID: 33775123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bronchopleural fistula arising after commencement of pazopanib for progressive sarcoma.
    Cohen L; Neuhaus S; Chryssidis S; Kotasek D
    ANZ J Surg; 2017 Jul; 87(7-8):E48-E49. PubMed ID: 25556827
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics.
    Yau T; Chen PJ; Chan P; Curtis CM; Murphy PS; Suttle AB; Gauvin J; Hodge JP; Dar MM; Poon RT
    Clin Cancer Res; 2011 Nov; 17(21):6914-23. PubMed ID: 21831954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors.
    Goh BC; Reddy NJ; Dandamudi UB; Laubscher KH; Peckham T; Hodge JP; Suttle AB; Arumugham T; Xu Y; Xu CF; Lager J; Dar MM; Lewis LD
    Clin Pharmacol Ther; 2010 Nov; 88(5):652-9. PubMed ID: 20881954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pazopanib in relapsed osteosarcoma patients: report on 15 cases.
    Longhi A; Paioli A; Palmerini E; Cesari M; Abate ME; Setola E; Spinnato P; Donati D; Hompland I; Boye K
    Acta Oncol; 2019 Jan; 58(1):124-128. PubMed ID: 30207179
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.